Answers are grounded in this paper and cite their sources.
Altered peptide ligands that alter immune responses are a promising approach to the immunotherapy of multiple sclerosis. Cyclic peptides are of interest because the limited stability of linear peptides restricts their use in vivo. We designed and synthesized a cyclic double mutant peptide from MBP(87-99)-[cyclo(87-99)[A(91),A(96)]MBP(87-99)]. Immunization of mice, in CFA reduced Th1 responses. However, when conjugated to reduced mannan, a significant further reduction of Th1 responses and moderate Th2 responses were induced.
No takes yet. Share an insight, caveat, or question.
Κατσάρα et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: